Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

271
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
271
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

661
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
661
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

151
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
151
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

254
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
254
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

202
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
202
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

585
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
585

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gastrointestinal symptom-specific anxiety is associated with disability in inflammatory bowel diseases independent of general anxiety and self-reported disease activity: evidence from a large cross-sectional patient study.

Journal of Crohn's & colitis·2026
Same author

Feasibility assessment of an emulsifier-free diet in healthy subjects - A sub-analysis of the FOAM trial.

Clinical nutrition ESPEN·2026
Same author

Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with noncomplicated or complex Crohn's disease: results from the EVOLVE Expansion study.

European journal of gastroenterology & hepatology·2026
Same author

Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's Disease.

Clinical pharmacokinetics·2026
Same author

Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Journal of Crohn's & colitis·2026
Same author

Identification of a Druggable Target That Predicts Postoperative Crohn's Disease Recurrence.

Gastroenterology·2026

Related Experiment Video

Updated: Nov 1, 2025

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
04:05

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Published on: May 31, 2024

609

Chronic Antibiotic-Refractory Pouchitis: Management Challenges.

An Outtier1, Marc Ferrante1

  • 1Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Clinical and Experimental Gastroenterology
|June 24, 2021
PubMed
Summary
This summary is machine-generated.

Pouchitis, a complication of ulcerative colitis surgery, affects up to 10% of patients. This review explores treatments for chronic antibiotic-refractory pouchitis, suggesting options similar to inflammatory bowel disease management.

Keywords:
biologicschronic antibiotic-refractory pouchitisinflammatory bowel disease

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

819
Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.2K

Related Experiment Videos

Last Updated: Nov 1, 2025

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
04:05

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Published on: May 31, 2024

609
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

819
Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.2K

Area of Science:

  • Gastroenterology
  • Surgical Complications
  • Inflammatory Bowel Disease

Background:

  • Pouchitis is the most frequent long-term complication following restorative proctocolectomy for ulcerative colitis.
  • Acute pouchitis affects up to 40% of patients within 5 years, with chronic antibiotic-refractory pouchitis developing in approximately 10%.

Purpose of the Study:

  • To conduct a narrative review of the existing literature on managing chronic antibiotic-refractory pouchitis.
  • To critically evaluate current treatment strategies and identify areas for future research.

Main Methods:

  • A comprehensive literature search was performed to identify relevant studies.
  • Published literature on the management of chronic antibiotic-refractory pouchitis was summarized and critically evaluated.

Main Results:

  • Clear classification of pouchitis (acute vs. chronic, antibiotic response) is needed, alongside validated severity scoring systems.
  • Treatments including antibiotics, aminosalicylates, steroids, immunomodulators, biologics, AST-120, hyperbaric oxygen, tacrolimus enemas, and apheresis have shown efficacy.
  • Secondary causes of pouchitis must be excluded before initiating treatment.

Conclusions:

  • Current therapeutic options for chronic antibiotic-refractory pouchitis are comparable to those for inflammatory bowel disease.
  • High-quality randomized controlled trials are essential to determine optimal treatment strategies for this patient group.